Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells

Proteoglycans are proteins that are modified with glycosaminoglycan chains. Chondroitin sulfate proteoglycans (CSPGs) are currently being exploited as targets for drug-delivery in various cancer indications, however basic knowledge on how CSPGs are internalized in tumor cells is lacking. In this stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2022-02, Vol.12 (1), p.3075-3075, Article 3075
Hauptverfasser: Wang, Chris Kedong, Nelepcu, Irina, Hui, Desmond, Oo, Htoo Zarni, Truong, Sarah, Zhao, Sarah, Tahiry, Zakir, Esfandnia, Shaghayegh, Ghaidi, Fariba, Adomat, Hans, Dagil, Robert, Gustavsson, Tobias, Choudhary, Swati, Salanti, Ali, Sorensen, Poul H., Al Nakouzi, Nader, Daugaard, Mads
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Proteoglycans are proteins that are modified with glycosaminoglycan chains. Chondroitin sulfate proteoglycans (CSPGs) are currently being exploited as targets for drug-delivery in various cancer indications, however basic knowledge on how CSPGs are internalized in tumor cells is lacking. In this study we took advantage of a recombinant CSPG-binding lectin VAR2CSA (rVAR2) to track internalization and cell fate of CSPGs in tumor cells. We found that rVAR2 is internalized into cancer cells via multiple internalization mechanisms after initial docking on cell surface CSPGs. Regardless of the internalization pathway used, CSPG-bound rVAR2 was trafficked to the early endosomes in an energy-dependent manner but not further transported to the lysosomal compartment. Instead, internalized CSPG-bound rVAR2 proteins were secreted with exosomes to the extracellular environment in a strictly chondroitin sulfate-dependent manner. In summary, our work describes the cell fate of rVAR2 proteins in tumor cells after initial binding to CSPGs, which can be further used to inform development of rVAR2-drug conjugates and other therapeutics targeting CSPGs.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-07025-6